Details

Autor(en) / Beteiligte

• Lawrenson, Kate
• Grun, Barbara
• Lee, Nathan
• Mhawech‐Fauceglia, Paulette
• Kan, Jenny
• Swenson, Steve
• Lin, Yvonne G.
• Pejovic, Tanja
• Millstein, Joshua
• Gayther, Simon A.

Titel

NPPB is a novel candidate biomarker expressed by cancer‐associated fibroblasts in epithelial ovarian cancer

Ist Teil von

• International journal of cancer, 2015-03, Vol.136 (6), p.1390-1401

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2015

Link zum Volltext

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Most solid tumors contain cancer‐associated fibroblasts (CAFs) that support tumorigenesis and malignant progression. However, the cellular origins of CAFs in epithelial ovarian cancers (EOCs) remain poorly understood, and their utility as a source of clinical biomarkers for cancer diagnosis has not been explored in great depth. Here, we report establishing in vitro and in vivo models of CAFs in ovarian cancer development. Normal ovarian fibroblasts and mesenchymal stem cells cultured in the presence of EOC cells acquired a CAF‐like phenotype, and promoted EOC cell migration in vitro. CAFs also promoted ovarian cancer growth in vivo in both subcutaneous and intraperitoneal murine xenograft assays. Molecular profiling of CAFs identified gene expression signatures that were highly enriched for extracellular and secreted proteins. We identified novel candidate CAF‐specific biomarkers for ovarian cancer including NPPB, which was expressed in the stroma of 60% primary ovarian cancer tissues (n = 145) but not in the stroma of normal ovaries (n = 4). NPPB is a secreted protein that was also elevated in the blood of 50% of women with ovarian cancer (n = 8). Taken together, these data suggest that the tumor stroma is a novel source of biomarkers, including NPPB, that may be of clinical utility for detection of EOC. What's new? Biomarkers that can reliably detect early‐stage ovarian cancer (EOC) are urgently needed. In this study, the authors found that NPPB, a protein not previously implicated in EOC, is upregulated by cancer‐associated fibroblasts in ovarian tumors, and was detected in the blood of half of the ovarian cancer patients tested. NPPB may, therefore, be a promising candidate as an ovarian‐cancer biomarker; these results also indicate that tumor stroma may be a useful source of cancer biomarkers.